DUBLIN, September 09, 2022--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company’s ordinary shares.
"This share repurchase program reinforces the confidence we have in our strategy and our commitment to deliver long-term value to our shareholders," said Tim Walbert, chairman, president and chief executive officer, Horizon. "Our strong balance sheet and cash generation gives us the flexibility to opportunistically repurchase shares while maintaining ample capital to continue prioritizing business development."
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions. Open market repurchases may be structured to occur in accordance with the requirements of Rule 10b-18 of the Securities Exchange Act of 1934. The Company may also enter into Rule 10b5-1 plans to facilitate repurchases of its shares under the program. The timing and amount of repurchases will depend on a variety of factors, including the price of the Company's ordinary shares, alternative investment opportunities, customary restrictions under the Company's debt agreements, corporate and regulatory requirements and market conditions. The program does not obligate the Company to repurchase any particular amount of its ordinary shares and the program may be modified, suspended or otherwise discontinued at any time without prior notice.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.
This press release contains forward-looking statements, including, but not limited to, statements related to Horizon’s strategy and potential future growth and value generation, the scope and execution of Horizon’s share repurchase program and expectations regarding the source of funds for the repurchase program. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties regarding whether, when and on what terms Horizon repurchases its ordinary shares under the program, changes in market conditions and alternative uses of Horizon’s capital, whether Horizon is able to grow its business and increase shareholder value over time, and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon’s filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005904/en/
Investors Relations: Tina Ventura Senior Vice President, Chief Investor Relations Officer Investor-relations@horizontherapeutics.com
U.S. Media: Geoff Curtis Executive Vice President, Corporate Affairs & Chief Communications Officer media@horizontherapeutics.com
Ireland Media: Gordon MRM Ray Gordon ray@gordonmrm.ie
David Trainer, the CEO of the investment research firm New Constructs, believes there are now roughly 300 publicly-traded zombie companies.
The bear market in software stocks has already lasted far longer than the typical decline, according to MoffettNathanson,
Inflation, interest rates, and recession – these are the bogeymen of investing, and they’ve been watching over our shoulders for the past several months. We all know the story by now, the rate of inflation is running at generational highs, the Federal Reserve is hiking rates in an attempt to push back against high prices, and that’s likely to tip the economy into recession. At a time like this, investors are showing a growing interest in finding strong defensive portfolio moves. It’s a mindset t
September more than lives up to its reputation as an ugly month for stocks. Here's what the data says about October performance.
Semiconductor stocks have tumbled in recent months amid flagging demand, with the S&P Semiconductors Select Industry Index dropping 36% year to date. Bank of America analysts recently discussed their favorite choices in the sector.
Leaving these accounts open could tarnish your golden years.
It's a tough S&P 500 stock market to make money on. But some investors are still finding a way to do it.
Overwhelming bearishness means stocks are reflecting "draconian earnings,” says David Baron of Baron Focused Growth.
It should be obvious that billionaires don’t accumulate wealth by accident. Their success is predicated on observation and savvy investment, and a privileged background helps. Billionaires like Microsoft Corp. co-founder Bill Gates likely saw an opportunity for land investment to return tenfold, by way of food shortages, well ahead of time. So it should be no surprise that the real estate investing platform Arrived Homes, backed by Amazon.com Inc. founder Jeff Bezos is taking off. He had the for
(Bloomberg) -- Mohamed El-Erian has a cautionary word for anyone anticipating an end to interest-rate increases from the Federal Reserve and other central banks.Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandMarjorie Taylor Greene’s Husband Files for Divorce After 27 YearsTop Apple Executive Is Leaving After Making Crude Remarks in TikTok VideoMeta to Cut Headcount for First Time, Slash Budgets Across TeamsWalmart, CVS Face Suits Blaming Common Painkiller f
Billionaire investor Stanley Druckenmiller sees a “hard landing” by the end of 2023 as the Federal Reserve’s aggressive monetary tightening will tip the U.S. economy into recession.
In financial markets, the tide is going out when central banks are raising interest rates and growth is slowing. That is to say, right now.
Yahoo Finance Live examines Carnival Cruise's stock after its latest earnings miss signifies a much longer path to profitability than expected.
MarketWatch Picks has highlighted these products and services because we think readers will find them useful; the MarketWatch News staff is not involved in creating this content. Since the start of the year, mortgage rates have been trending upwards — and according to many experts, this trend will likely continue through October. Echoing that sentiment, Kate Wood, home expert at NerdWallet, says interest rates for 30-year fixed-rate loans appear to be staying over 6% and products like the 15-year fixed and the 5-year ARMs are averaging over 5%.
These top-tier companies are begging to be bought following a 34% peak decline in the Nasdaq Composite.
The recent bear market has considerably reduced the appeal of most stocks. With many growth stocks down 75% or more from their highs, investors have increasingly looked to other investment vehicles. Three discounted tech stocks that would make great permanent additions to your portfolio are Microsoft (NASDAQ: MSFT), Axon Enterprise (NASDAQ: AXON), and Zoom Video Communications (NASDAQ: ZM).
A quick glance at the iShares Semiconductor ETF, which has lost 40% of its value this year, shows the extent of the damage. Shifting consumer spending patterns are leading to lower demand for chips used in personal computers and electronics, while supply chain disruptions are making it difficult to produce enough of the products that remain in high demand. Advanced Micro Devices (NASDAQ: AMD) hasn't been spared from the wreckage.